(NASDAQ: LXRX) Lexicon Pharmaceuticals's forecast annual revenue growth rate of 13.17% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 64.61%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.18%.
Lexicon Pharmaceuticals's revenue in 2025 is $31,081,000.On average, 3 Wall Street analysts forecast LXRX's revenue for 2025 to be $5,578,910,589, with the lowest LXRX revenue forecast at $3,289,579,885, and the highest LXRX revenue forecast at $7,988,979,720. On average, 4 Wall Street analysts forecast LXRX's revenue for 2026 to be $7,223,339,039, with the lowest LXRX revenue forecast at $3,651,072,180, and the highest LXRX revenue forecast at $17,243,182,472.
In 2027, LXRX is forecast to generate $18,139,683,363 in revenue, with the lowest revenue forecast at $5,458,533,655 and the highest revenue forecast at $38,354,332,500.